SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1465)8/25/2000 9:33:46 AM
From: Elmer  Read Replies (1) | Respond to of 52153
 
Thank Richard, The following is a draft of your suggested e-mail to DNDN IR:
"Thanks for your previous responses. Can you describe how the Mylovenge project differs from the vaccine work undertaken by IDEC Pharmaceuticals about 10 years ago?

Also, I understand that Vical has a Phase I/II trial ongoing for a cancer vaccine for lymphoma. Did this trial influence the company's selection of multiple myeloma as an initial focus? If the Vical trials are successful, how will this effect Mylovenge's competitive picture?"

Does this capture the questions you want answered?

David



To: scaram(o)uche who wrote (1465)8/26/2000 5:49:24 PM
From: Elmer  Read Replies (1) | Respond to of 52153
 
Hi Richard,
Rob Toth of Prudential authored a report on DNDN on 8-14-00 titled "Immunization Against Cancer May Soon Become Reality." It's forty pages long and cost $75. I haven't purchased it yet. Do you think it would come close to addressing the issues you've raised?

see link.multexinvestor.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News